Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Glenmark receives approval for combination of Remogliflozin Etabonate and Metformin Hydrochloride for adults with type 2 diabetes in India

Posted On: 2019-08-19 18:40:32

Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that the company has received regulatory approval to market a combination of its novel, patent protected and globally-researched sodium glucose co-transporter-2 (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) and Metformin Hydrochloride (Metformin) film coated tablets in India. The drug is indicated in the treatment of type-2 diabetes mellitus in adults. Glenmark will commercialize the product under the brand names 'Remo-M' and Remozen-M'.

Earlier in April 2019, Glenmark received regulatory approval for Remogliflozin etabonate 100 mg tablets, twice daily, aftersuccessfully completing Phase-3 clinical trials in which Remogliflozin demonstrated good efficacy and safety profile in a head-to-head comparison against Dapagliflozin. With this approval Glenmark became the first company in the world to launch the novel SGLT2 inhibitor Remogliflozin with India being the first country to get access to this innovative drug. Glenmark subsequently launched Remogliflozin in India under the brand names 'Remo' and 'Remozen'.

Glenmark has now received regulatory approval for a combination of Remogliflozin and Metformin film coated tablets. The approved dosage strengths are 100 mg of Remogliflozin combined with either 500 mg or 1,000 mg of Metformin. This combination is indicated as an adjunct to diet and exercise to improve glycemic control in type-2 diabetes mellitus patients(for full indication, it is advisable to refer the package insert).

"The approval for Remogliflozin and Metformin combination is a testament of our commitment towards revolutionizing diabetes management in India. Glenmark is a pioneer in providing access to the latest treatment options to diabetes patients in India. Earlier this year, we launched Remogliflozin with an aim to increase patients' access to SGLT2 inhibitors as this class of drugs have proven benefits for effective diabetes management. As the prevalence of diabetes continues to rise rapidly, we are pleased to offer an additional treatment option to patients. This approval for combination of Remogliflozin and Metformin will only help us get closer to our goal of providing an effective, high quality and world-class treatment option and improving access to SGLT2 inhibitors for patients in India," said Sujesh Vasudevan, President, India Formulations, Middle East and Africa at Glenmark Pharmaceuticals.

The company had launched Remogliflozin as a mono-therapy, at a breakthrough price which is over 50% lower than the existing SGLT2 inhibitors available in India. Prior to the launch of Remogliflozin, the average per day therapy cost of SGLT2 inhibitors in India was about Rs. 55.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.368.15 as compared to the previous close of Rs. 361.1. The total number of shares traded during the day was 72121 in over 1829 trades.

The stock hit an intraday high of Rs. 372.25 and intraday low of 360. The net turnover during the day was Rs. 26503702.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Morgan Credits Private Limited has sold 2.3% stake in YES Bank Ltd

AXIS Bank opens QIP, fixes floor price as Rs. 661.50

Lux Industries Limited issues CPs of Rs. 50 crore

Godrej Consumer Products Ltd increases stake in subsidiaries

ICRA reaffirms ratings of Reliance Chemotex Industries Ltd

Lincoln Pharmaceuticals Ltd board approves merger of Lincoln Parenteral Ltd

Thyrocare Technologies Ltd calls for board meeting on Sep 21, 2019

Capital India Finance Ltd inks MOU with Union Bank of India for Loan Co-origination

Morepen Laboratories Ltd board approves preferential issue

Mahindra BAJA SAEINDIA 2020 Commences its 13th edition

NMDC revises prices of Iron Ore w.e.f. 19-09-2019

Speedcast and Nelco Awarded Remote Communications Contract for Leading Indian Cruise Line

Bharat Forge Ltd acquisition update regarding Refu Drive GmbH

Kolte-Patil Developers delivers strong returns to Motilal Oswal Real Estate from its City Avenue Project

Astral Poly Technik Limited allots 3,01,32,441 bonus shares

Surya Roshni Ltd bags order of Rs.79.80 crore

TCS a Leader in Software Product Engineering Services: Everest Group

Thomas Cook India observes an impressive 21% growth in demand during Durga Puja

Now buy Detel TVs and connected essentials in IndiGo flights

TVS Motor Company launches TVS NTORQ 125 Race Edition

IDBI Bank board approves preferential issue to Government and LIC

1 millionth Maruti Suzuki car exported from Gujarat's Mundra Port

Mindtree Opens New European Headquarters in London

U.S. FDA issues Warning Letter for Lupin's Mandideep, Unit-1 facility

Ambuja Cements among the top 4 in global DJSI ranking

Ultratech Cement Limited Ranked Among The TOP 10 Companies Globally Under 'Construction Material' In The DJSI Index

CRISIL reaffirms ratings of Advanced Enzyme Technologies Ltd

Tata Communications and Cisco partner to create a fully managed contact centre solution for enhanced customer experience

Global Operators Collaborate with Industry Partners to Facilitate O-RAN Testing and Integration

Allahabad Bank launches retail loans linked with RBI's Repo Rate and 3 months MIBOR

Reliance Capital denies invocation of pledged RNAM shares

Madhav Infra Projects Ltd secures orders for road projects and solar project

Insilco restarts plant operations from Sep 18, 2019

ICRA affirms ratings of Hindustan Tin Works Ltd

Laurus Labs Ltd to acquire Phekolong Pharmaceuticals Pty Ltd

ICRA Ltd revises outlook on OBC's bonds

ICRA reaffirms commercial paper rating of Mahindra CIE Automotive Limited

Premier Explosives Ltd updates on successful test-firing of Astra Missile by IAF

Federal Bank's New Branch at Velachery Opened

Wipro positioned as a Leader in Gartner's Magic Quadrant for Data Center Outsourcing and Hybrid Infrastructure Managed Services, North America

RITES Ltd signs major export contract of $22.4 mn

SHARP Launches Its Range of Smart Home Appliances in India to Kick Off the Festive Season

FlexiLoans.com crosses Rs. 500 Crores Business Loans disbursal

mjunction's 13th Indian Coal Markets Conference begins

IDFC Ltd board to consider interim dividend on Sep 21, 2019

Oriental Bank of Commerce board approves merger

Emagia Announces AI-Powered Digital Receivables For Oracle ERP Cloud

Wipro positioned as a Leader in Gartner's Magic Quadrant for Data Center Outsourcing and Hybrid Infrastructure Managed Services, Asia / Pacific

Indian Bank approves merger approval, fund raising

Endurance Technologies Ltd commences commercial production at Kolar plant







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019